688266.SS SHH
Suzhou Zelgen Biopharmaceuticals Co., Ltd.
1W: -7.2%
1M: -6.5%
3M: -19.3%
YTD: +14.6%
1Y: +3.6%
3Y: +131.0%
5Y: +46.2%
¥110.00 ($16.41)
+3.34 (+3.13%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
-$19M
-149.9% ▼
Capital Expenditures
$181M
-89.6% ▼
5Y CAGR: +25.8%
Free Cash Flow
-$201M
-248.9% ▼
Dividends Paid
$0
+100.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$122M
+93.4% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$462M | -$486M | -$295M | -$150M | -$163M |
| Depreciation & Amort. | $51M | $66M | $55M | $56M | $56M |
| Stock-Based Comp. | $35M | $37M | $0 | $0 | $0 |
| Change in Working Capital | -$78M | $219K | $25M | $155M | $109M |
| Other Non-Cash Items | $3M | $14M | -$5M | -$22M | -$16M |
| Operating Cash Flow | -$455M | -$370M | -$220M | $38M | -$19M |
| — Investing Activities — | |||||
| Capital Expenditures | -$71M | -$89M | -$63M | -$96M | -$181M |
| Acquisitions (Net) | -$8M | -$24M | $0 | $0 | -$80M |
| Investment Purchases | -$520M | -$943M | -$1.1B | -$3.0B | $0 |
| Investment Sales | $917M | $768M | $1.2B | $1.2B | $116M |
| Other Investing | $8M | $24M | $3K | $0 | $0 |
| Investing Cash Flow | $327M | -$264M | $52M | -$1.8B | -$146M |
| — Financing Activities — | |||||
| Net Debt Issuance | $106M | $318M | $354M | $153M | $117M |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | -$4M | -$11M | -$21M | -$25M | $0 |
| Other Financing | -$8M | -$24M | $1.2B | -$180M | -$44M |
| Financing Cash Flow | $94M | $283M | $1.5B | -$51M | $73M |
| Net Change in Cash | -$35M | -$348M | $1.3B | -$1.9B | -$122M |
| Cash End of Period | $1.1B | $736M | $2.1B | $217M | $2.0B |
| Free Cash Flow | -$525M | -$459M | -$295M | -$57M | -$201M |